Genetic variation in CYP3A43 explains racial difference in olanzapine clearance
Open Access
- 26 April 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Psychiatry
- Vol. 16 (6), 620-625
- https://doi.org/10.1038/mp.2011.38
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- International Consensus Study of Antipsychotic DosingAmerican Journal of Psychiatry, 2010
- Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patientsEuropean Journal of Clinical Pharmacology, 2010
- Sequence diversity and haplotype structure at the human CYP3A clusterThe Pharmacogenomics Journal, 2005
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaThe New England Journal of Medicine, 2005
- Clinical outcome and olanzapine plasma levels in acute schizophreniaEuropean Psychiatry, 2005
- The International HapMap ProjectNature, 2003
- The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol DevelopmentSchizophrenia Bulletin, 2003
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- OlanzapineClinical Pharmacokinetics, 1999
- In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3ABritish Journal of Clinical Pharmacology, 1996